Nurse Anesthetist - CR in Twentynine Palms, CA Accepting Medicare

7 Nurse Anesthetist - CR nurses found. Showing 1 - 7

Rodrigo Fernando Lopez, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1145 Sturgis Road, Naval Hospital Twentynine Palms, Twentynine Palms, CA 92278 Phone: 760-830-2290

Mark Thomas Sebald, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 1145 Sturgis Rd, Twentynine Palms, CA 92278 Phone: 713-614-3078

Mr. Martin Francis O'connor, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: Naval Hospital Attn Professional Affairs, Magtftc Mcagcc Box 788250, Twentynine Palms, CA 92278 Phone: 760-830-2292

John Dilgard, CRNA Nurse Anesthetist, Certified Registered Medicare: Medicare Enrolled Practice Location: 1145 Sturgis Rd, Twentynine Palms, CA 92278 Phone: 208-284-6154

Dr. Jeremiah D. Bond, DNP, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1145 Sturgis Rd., Twentynine Palms, CA 92278 Phone: 904-651-7007

Samantha Jean Filipovich, CRNA, DNP Nurse Anesthetist, Certified Registered Medicare: Medicare Enrolled Practice Location: 1145 Sturgis Road, Twentynine Palms, CA 92278 Phone: 760-830-2117

Zachary Ryan Visnic, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1145 Sturgis Road, Naval Hospital Twentynine Palms, Twentynine Palms, CA 92278 Phone: 760-830-2117

News Archive

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

Research into 'personalised' medicine is being led by Greenwich team

Research into 'personalised' medicine is being led by a University of Greenwich team. Currently, many medicines which are prescribed to patients either do not work properly or have some significant side effects. The aim of personalised medicine, sometimes called 'precision' medicine, is to ensure that the most appropriate medicine is given to each patient and that the medicine is both effective and safe.

Sex differences in health awareness

A majority of American women always or frequently read the labels of their prescribed or over the counter medications to see if they might work differently in women, but few discuss this issue with their doctor or pharmacist, according to a new survey released by the Society for Women's Health Research, a Washington, D.C., based advocacy organization.

Read more Medical News

› Verified 8 days ago